Study Finds 6 Alzheimer’s Molecular Subgroups Shared Across 3 Population Groups
Updated
Updated · Nature.com · Jul 15
Study Finds 6 Alzheimer’s Molecular Subgroups Shared Across 3 Population Groups
2 articles · Updated · Nature.com · Jul 15
Summary
Researchers profiled 1.9 million brain-cell nuclei from 167 donors and found Alzheimer’s-linked cell signatures recurring across Latin, white and African American groups rather than appearing confined to one population.
The strongest shared signal was a rise in GPNMB-positive microglia in cortical regions tied to dementia, faster cognitive decline and higher tau burden; region-specific astrocyte and vulnerable neuronal signatures also repeated across groups.
Factor-based analysis added disease-linked astrocyte and oligodendrocyte gene programs that discrete cell clusters missed, highlighting pathways tied to lipid processing, immune signaling and neurotransmitter reuptake.
Six molecular subgroups of cognitively impaired donors emerged in the superior temporal gyrus, spanning all three populations and not separated by standard pathology measures such as Braak stage or CERAD scores.
The authors say the findings support more representative Alzheimer’s sampling for target discovery and patient stratification, though snATAC-seq depth and subgroup sample sizes limited power for population-specific effects.
If Alzheimer's has shared biological roots, why do its signs and diagnoses differ so starkly across racial lines?
Beyond amyloid, will future Alzheimer's treatments be tailored to one of six newly discovered molecular forms of the disease?
Six Molecular Subgroups of Alzheimer’s Disease Discovered: A New Era for Precision Diagnosis and Treatment
Overview
A major study published in 2026 revealed that Alzheimer’s disease is not a single disorder, but a spectrum made up of six distinct molecular subgroups. This discovery challenges the traditional view of Alzheimer’s and shows that the disease’s molecular differences appear from early cognitive changes to advanced dementia. Three subgroups are linked to mild cognitive impairment, while the other three are mostly found in people with Alzheimer’s dementia. This new understanding opens the door to more targeted diagnosis and treatment, moving away from a one-size-fits-all approach and paving the way for personalized care in Alzheimer’s disease.